Discussing the DESTINY-Breast04 study which resulted in a paradigm shift, with the introduction of low HER2 positive breast cancer, and further approval of Trastuzumab Deruxtecan (T-DXd). In discussion with the lead author, Dr. Shanu Modi - Professor of Medicine at Memorial Sloan Kettering Cancer Center.
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
